Today's guest is Daniel Ferrante, AI Leader in R&D and Data Strategy at Deloitte. Together with Emerj CEO and Head of Research Daniel Faggella, they delve into the complex challenges in AI adoption that major pharmaceutical firms encounter with cultural shifts, technological complexities, and the difficulties in monetizing data and aligning teams efficiently. Additionally, the pair explores the future landscape of phenotypical drug discovery, drawing insights from the context of COVID-19. Their focus underscores the critical importance of collecting and analyzing data to yield actionable insights, especially in the healthcare sector and amidst global health crises. If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!